Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive Minimal Residual Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 06720
- Recruiting
- Hospital General de México "Dr. Eduardo Liceaga"
-
Contact:
- Christian O Ramos Peñafiel, PhD
- Phone Number: 2020 +52 55 2789 2000
- Email: leukemiachop@hotmail.com
-
Sub-Investigator:
- Carlos Martínez Murillo, PhD
-
Sub-Investigator:
- Humberto Castellanos Sinco, PhD
-
Sub-Investigator:
- Odín de la Mora Estrada, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a confirmatory diagnosis of Acute Lymphoblastic Leukemia relapsed to bone marrow described with more than 5% blasts in bone marrow at any stage of treatment or positivity of minimal residual disease at any stage of treatment.
- Patients who have signed their informed consent from the institution for hospitalization, and accepted the performance of the bone marrow study, and the administration of chemotherapy.
Exclusion Criteria:
- Patients with a diagnosis of phenotypic leukemia or bilinear leukemia
- Patients treated only with palliative regimen or transfusion support
- Patients without the administration of prophylaxis to the central nervous system by intrathecal chemotherapy
- Patients with lymphoblastic leukemia with a positive Philadelphia chromosome
- Patients with severe comorbidities may put treatment therapy at risk.
- Patient with a history of cardiac toxicity or arrhythmias associated with treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NO_INTERVENTION: Standard Care Group
Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks.
Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
|
|
|
EXPERIMENTAL: Bortezomib Treatment Group
Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks.
Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
|
Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival Outcome
Time Frame: 3 months
|
The event in which patient is discharge from Hospital stay.
|
3 months
|
|
Hospital stay
Time Frame: 3 months
|
Time in which patients stay in the Hospital before discharge
|
3 months
|
|
Leukocytes count
Time Frame: 3 months
|
Number of leukocytes found in peripheral blood at the end of each chemotherapy cycle
|
3 months
|
|
Platelets count
Time Frame: 3 months
|
Number of platelets found in peripheral blood at the end of each chemotherapy cycle
|
3 months
|
|
Date of Remission
Time Frame: 3 month
|
Time in which the patient completes remission
|
3 month
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7.
- Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4935-9. doi: 10.1073/pnas.91.11.4935.
- Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo MG, Girardi K, Trevisan V, Bertaina V, Merli P, Locatelli F. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Neoplastic Processes
- Leukemia
- Recurrence
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Neoplasm, Residual
- Antineoplastic Agents
- Bortezomib
Other Study ID Numbers
Other Study ID Numbers
- HGMDI/21/204/03/67
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.